A morbidly obese diabetic woman was on failed metformin therapy. She has the history of pancreatitis and family history of bladder cancer. Patient does not want to take injections. Which of the following would be suitable to reduce her glucose levels?
(A) Liraglutide (B) Sitagliptin (C) Canagliflozin (D) Pioglitazone
(C) Ans. C. Canagliflozin Canagliflozin is a Sodium-Glucose Co-Transpoer 2 Inhibitor, given orally and reduces body weight. For the given clinical scenario, Canagliflozin is the preferred drug, as Sitagliptin increases the risk of acute pancreatitis, use of pioglitazone is associated with a small increased risk of bladder cancer and Liraglutide is given subcutaneously.